Memorial Sloan Kettering Cancer Center
The researchers are doing this study to improve their knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma by collecting information from participants' medical records who have been treated with immune checkpoint blockade or T-cell receptor-based therapy.
Inclusion Criteria: * Participants must have a histologic diagnosis of sarcoma confirmed by an MSK pathologist. * Any prospectively identified patient being treated or to be treated with an immune checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG3 inhibitor, either as monotherapy or in combination with additional systemic therapy OR any prospectively identified patient being treated or to be treated with ACT-based treatment including but not limited to lifileucil, Afamitresgene autoleucel, and letetresgene autoleuce o Novel immune checkpoints inhibitors that are de…